Prognostic marker for endometrial carcinoma

摘要

The present invention relates to a method for diagnosing or determining the status of endometrial carcinoma in an individual afflicted with or suspected to be afflicted with endometrial carcinoma based on the phosphorylated stathmin compound whereby said stathmin is phosphorylated at position Serine 38. Moreover, the present invention relates to a method for evaluating the probability of survival, the clinical outcome or the treatment course of an individual afflicted with or suspected to be afflicted with endometrial carcinoma. In another aspect, the present invention relates to the stratification of the therapeutic regimen of an individual with endometrial carcinoma. In particular, the present invention provides a method for diagnosing or identifying endomentrial carcinoma with high grade aggressive phenotype, in particular, having low response and susceptibility to chemotherapeutic regimen, in particular, with respect to micro-tubule stabilization based regimen including treatment with taxanes. Moreover, the present invention relates to a kit for use in any of the above-referenced methods comprising means for determining the level or amount of phosphorylated pStathmin(S38) as well as assays for conducting the method according to the present invention. In one embodiment, the methods according to the present invention include the combined determination of stathmin and phosphorylated stathmin (pStathmin(S38)).